ESCAPE Bio is a clinical-stage, privately-held biopharmaceutical company developing novel, precisely-targeted therapeutics for genetically-defined neurodegenerative diseases. ESB1609 is in a Phase 1, randomized, double-blind, placebo-controlled, safety, tolerability, pharmacokinetic and biomarker study of escalating multiple doses in healthy volunteers. ESCAPE’s pipeline includes small molecules targeting known genetic drivers of CNS disorders, including ESB1609, an S1P5 agonist for the treatment of CNS lysosomal storage disorders and GBA Parkinson’s; a G2019S-selective kinase inhibitor for Parkinson’s Disease (PD) patients with that mutation; and an Alzheimer's disease program targeting ApoE4. For additional information, please visit www.escapebio.com.